[HTML][HTML] The inflammatory profile of the tumor microenvironment, orchestrated by cyclooxygenase-2, promotes epithelial-mesenchymal transition
F Gómez-Valenzuela, E Escobar… - Frontiers in …, 2021 - frontiersin.org
The tumor microenvironment (TME) corresponds to a complex and dynamic interconnection
between the extracellular matrix and malignant cells and their surrounding stroma …
between the extracellular matrix and malignant cells and their surrounding stroma …
Biomarkers for malignant pleural mesothelioma—a novel view on inflammation
M Vogl, A Rosenmayr, T Bohanes, A Scheed… - Cancers, 2021 - mdpi.com
Simple Summary In view of the recent advances in immunoncology, we want to reevaluate
and summarize the role of the immune system in malignant pleural mesothelioma (MPM) …
and summarize the role of the immune system in malignant pleural mesothelioma (MPM) …
Celecoxib repurposing in cancer therapy: molecular mechanisms and nanomedicine-based delivery technologies
While cancer remains a significant global health problem, advances in cancer biology, deep
understanding of its underlaying mechanism and identification of specific molecular targets …
understanding of its underlaying mechanism and identification of specific molecular targets …
[HTML][HTML] PACER lncRNA regulates COX-2 expression in lung cancer cells
SZ Desind, JR Iacona, YY Christina, A Mitrofanova… - Oncotarget, 2022 - ncbi.nlm.nih.gov
Long noncoding RNAs (lncRNAs) are known to regulate gene expression; however, in many
cases, the mechanism of this regulation is unknown. One novel lncRNA relevant to …
cases, the mechanism of this regulation is unknown. One novel lncRNA relevant to …
表皮生长因子受体敏感突变肺癌靶向治疗原发耐药的机制及临床对策
梁文华, 黎才琛, 梁恒瑞, 赵毅, 李凤, 钟然, 熊珊… - 中国全科医学, 2021 - chinagp.net
针对伴有表皮生长因子受体(EGFR) 敏感突变的非小细胞肺癌, 基于小分子抑制剂的靶向治疗在
临床上取得了极大成效, 但仍面临着原发耐药/不敏感的问题. 初始治疗的有效比例及疗效深度 …
临床上取得了极大成效, 但仍面临着原发耐药/不敏感的问题. 初始治疗的有效比例及疗效深度 …
12 Drug repurposing of selective COX-2 inhibitors in the pursuit of new therapeutic avenues
N Saha, S Biswas, A Kumar, AK Chakraborti - Drug Repurposing - degruyter.com
Drug repurposing is an alternative and effective strategy in drug discovery. Compared to the
de novo drug discovery approach, drug repurposing is a rapid process to identify new uses …
de novo drug discovery approach, drug repurposing is a rapid process to identify new uses …
Можливості застосування ацетилсаліцилової кислоти та інших нестероїдних протизапальних препаратів для зменшення онкологічного ризику (огляд …
Анотація Мета роботи–аналіз та узагальнення відомостей сучасної фахової
літератури щодо можливості застосування ацетилсаліцилової кислоти (АСК) та інших …
літератури щодо можливості застосування ацетилсаліцилової кислоти (АСК) та інших …
[PDF][PDF] Biomarkers for Malignant Pleural Mesothelioma—A Novel View on Inflammation. Cancers 2021, 13, 658
M Vogl, A Rosenmayr, T Bohanes… - Malignant …, 2021 - researchgate.net
Malignant pleural mesothelioma (MPM) is an aggressive disease with limited treatment
response and devastating prognosis. Exposure to asbestos and chronic inflammation are …
response and devastating prognosis. Exposure to asbestos and chronic inflammation are …